Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Access this Article

Author(s)

    • Senoo Satoru
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Hotta Katsuyuki
    • Center for Innovative Clinical Medicine, Okayama University Hospital, Japan
    • Maeda Yoshinobu
    • Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
    • Kiura Katsuyuki
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Makimoto Go
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Nishii Kazuya
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Kano Hirohisa
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Watanabe Hiromi
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Hata Yusuke
    • Department of Respiratory Medicine, Okayama University Hospital, Japan|Department of Respiratory Medicine, Kure Kyosai Hospital, Japan
    • Kubo Toshio
    • Department of Respiratory Medicine, Okayama University Hospital, Japan
    • Tanaka Takehiro
    • Division of Diagnostic Pathology, Okayama University Hospital, Japan

Abstract

<p>Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1<sup>+</sup>, CD68<sup>+</sup> and CD206<sup>+</sup> macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1<sup>+</sup> macrophage infiltration. </p>

Journal

  • Internal Medicine

    Internal Medicine 58(7), 985-989, 2019

    The Japanese Society of Internal Medicine

Codes

Page Top